2002-03-11
Altered irinotecan metabolism in a patient receiving phenytoin
Publication
Publication
Anti-Cancer Drugs , Volume 13 - Issue 2 p. 139- 140
The systemic exposure to the anticancer agent irinotecan (CPT-11) and its active metabolite SN-38 were 79 and 92% reduced, respectively, relative to literature data, by concomitant phenytoin therapy. This finding suggests that increased doses of CPT-11 should be given to patients treated simultaneously with these drugs, to achieve adequate levels of SN-38. [
| Additional Metadata | |
|---|---|
| , , | |
| doi.org/10.1097/00001813-200202000-00004, hdl.handle.net/1765/68023 | |
| Anti-Cancer Drugs | |
| Organisation | Department of Medical Oncology |
|
Mathijssen, R., Sparreboom, A., Dumez, H., van Oosterom, A., & de Bruijn, E. (2002). Altered irinotecan metabolism in a patient receiving phenytoin. Anti-Cancer Drugs, 13(2), 139–140. doi:10.1097/00001813-200202000-00004 |
|